GlassScriptPhysician profile
Heather A Hebert
NPI 1093825382
$8,663.38
in general payments reported to CMS, 2019-2025
20 companies · $5,480 in 2025
The $5,480 reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $343 · 2022: $643 · 2023: $1,075 · 2024: $1,123 · 2025: $5,480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,100 · Food and Beverage: $3,128 · Travel and Lodging: $365 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,100.00 |
| Food and Beverage | $3,127.89 |
| Travel and Lodging | $365.40 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $4,913.93 | 2024-2025 | Voquezna |
| Abbvie INC. | $1,364.16 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $595.51 | 2021-2025 | Trulance, Xifaxan |
| Genzyme Corporation | $419.90 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $264.29 | 2022-2025 | Entyvio |
| Ardelyx, INC. | $217.34 | 2023-2024 | Ibsrela |
| Evoke Pharma, INC. | $208.30 | 2023-2024 | Gimoti |
| Janssen Biotech, INC. | $178.86 | 2024-2025 | Tremfya, Stelara |
| Celgene Corporation | $155.53 | 2022-2024 | Zeposia |
| Incyte Corporation | $124.99 | 2025 | Zynyz |
| Lilly USA, LLC | $53.55 | 2024 | Omvoh |
| Daiichi Sankyo INC. | $38.18 | 2022-2023 | Injectafer |
| Qol Medical, LLC | $21.89 | 2023 | Sucraid |
| Redhill Biopharma INC. | $18.20 | 2021 | |
| Madrigal Pharmaceuticals | $17.17 | 2025 | Rezdiffra |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $15.05 | 2025 | Wegovy |
| Vivus LLC | $14.99 | 2022 | |
| Braintree Laboratories, INC. | $14.29 | 2024 | Sutab, Suflave |
| Axonics, INC. | $14.06 | 2021 | |
| Nestle Healthcare Nutrition INC. | $13.19 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Hebert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.